Short Interest in Quantum Biopharma Ltd. (NASDAQ:QNTM) Increases By 63.2%

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the target of a large growth in short interest in January. As of January 30th, there was short interest totaling 76,665 shares, a growth of 63.2% from the January 15th total of 46,986 shares. Based on an average daily trading volume, of 65,698 shares, the short-interest ratio is presently 1.2 days. Currently, 2.2% of the company’s stock are sold short. Currently, 2.2% of the company’s stock are sold short. Based on an average daily trading volume, of 65,698 shares, the short-interest ratio is presently 1.2 days.

Hedge Funds Weigh In On Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Jane Street Group LLC bought a new position in Quantum Biopharma Ltd. (NASDAQ:QNTM) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,892 shares of the company’s stock, valued at approximately $80,000. Jane Street Group LLC owned approximately 0.29% of Quantum Biopharma at the end of the most recent reporting period. 1.24% of the stock is owned by institutional investors and hedge funds.

Quantum Biopharma Stock Performance

Shares of Quantum Biopharma stock traded down $0.01 on Friday, hitting $3.64. The company had a trading volume of 21,125 shares, compared to its average volume of 69,779. Quantum Biopharma has a 1 year low of $3.62 and a 1 year high of $38.25. The stock has a 50 day moving average of $6.88 and a 200-day moving average of $12.34. The stock has a market capitalization of $13.90 million, a price-to-earnings ratio of -0.33 and a beta of 0.30.

Analyst Ratings Changes

QNTM has been the subject of a number of research reports. Wall Street Zen cut Quantum Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday, January 24th. Weiss Ratings reissued a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma presently has a consensus rating of “Sell”.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.